Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ TLX3 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA583146
Description
Immunogen sequence: APFEDAGSYS VNLSLAPAGV IRVPAHRPLP GAVPPPLPSA LPAMPSVPTV SSLGGLNFPW MESSRRFVKD RFTA.
The Hox proteins play a role in patterns of embryonic development and cellular differentiation by regulating downstream target genes. TLX3, also known as homeobox11-like1 (HOX11L2), is a DNA-binding nuclear transcription factor that is expressed in a subset of the primary sensory nervous system. TLX3, along with the related TLX1, is a selector transcription factor that promotes an excitatory glutamatergic neuronal phenotype over an inhibitory GABAergic phenotype opposing LBX1 signals during dorsal spinal cord development. Chromosomal translocations of the TLX3 gene have been shown to result in some forms of T-cell acute lymphoblastic leukemia (T-ALL).
Specifications
TLX3 | |
Polyclonal | |
Unconjugated | |
TLX3 | |
homeo box 11-like 2; homeobox 11-like 2; homeobox protein Hox-11L2; Homeobox TLX-3; HOX11L2; Respiratory neuron homeobox protein; RGD1564190; RNX; T cell leukemia, homeobox 3; T-cell leukemia homeobox 3; T-cell leukemia homeobox protein 3; T-cell leukemia, homeobox 3; Tlx1l2; TLX3 | |
Rabbit | |
Antigen Affinity Chromatography | |
RUO | |
30012 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunocytochemistry | |
0.08 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
O43711 | |
TLX3 | |
Recombinant protein corresponding to Human TLX3. Recombinant protein control fragment (Product #RP-108335). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction